comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-27 19:29:14 - browse：4179

Ron Wyden (left), Mike Crapo (right) -- health policy coverage from STAT — Draft legislation authored by Senate Finance Chair Ron Wyden (D-Ore.) and ranking member Mike Crapo (R-Idaho) includes several measures to regulate how pharmacy benefit managers are paid by health plans to negotiate with drugmakers. Pete Marovich-Pool/Getty Images

WASHINGTON — A key Senate health care panel has developed a plan to tackle reforms to middlemen in the pharmacy drug payment system, according to bill text obtained by STAT.

The draft legislation, authored by Senate Finance Chair Ron Wyden (D-Ore.) and ranking member Mike Crapo (R-Idaho), includes several measures to regulate how pharmacy benefit managers are paid by health plans to negotiate with drugmakers.

The most significant measure is a bill from Sens. Bob Menendez (D-N.J.) and Marsha Blackburn (R-Tenn.) that would prohibit PBMs from getting any income outside of service fees, and prohibits those service fees from being related to drugs’ list prices.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Listen: PBM conflicts, RSV vaccines, & the future of flu season

focus

WSS

7 people shot in DC, police say

Studies point to risks of excluding people with obesity from drug trials

Medicare reduced heart disease by changing how it pays doctors

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

Listen: PBM conflicts, RSV vaccines, & the future of flu season

Option Care buys Amedisys in $3.6 billion home care deal

knowledge

comprehensive

focus

The cancer drug shortage isn’t new — and neither are the solutions

Listen: Biogen's messy board & Laronde's data problem

BioMarin wins approval for gene therapy to treat hemophilia A

Did the public have the right to know Arthur Ashe had AIDS?

Moonlake's readout produced a cash windfall. Risks remain

Beam Therapeutics to lay off 20% of its staff, re

Duchenne breakthrough therapy leaves behind pioneering families

A new study asks: Are we harming blood donors by taking blood?

How to save PrEP access — and even expand it

Grail is spending more than ever lobbying Congress

hotspot

NIH confirmation hearing shows politicization of research

Pfizer's Covid pill remains 89% effective in final analysis, company says

Australia's humpback populations rebound raising hopes of marine scientists

Impact of Dobbs ruling felt at reproductive medicine meeting

Impact of Dobbs ruling felt at reproductive medicine meeting

PhRMA sues HHS over Medicare drug price negotiation

focus

focus

explore

explore